Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03132922 · OUTCOME

Overall Survival (OS)

MAGE-A4ᶜ¹º³²T for Multi-Tumor · Source last updated 2026-06-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Weeks
Interval / dispersion
95% Confidence Interval
Time frame
From afamitresgene autoleucel infusion until death due to any reason or censored date From afamitresgene autoleucel infusion until death due to any reason or censored date

What was measured

OS was defined as the time from the date of afamitresgene autoleucel infusion to the date of death (due to any reason).

Groups in this outcome

Afamitresgene Autoleucel, Group 1

Participants who received afamitresgene autoleucel 0.1x10\^9 transduced cells

Afamitresgene Autoleucel, Group 2

Participants who received afamitresgene autoleucel 0.5-1.2x10\^9 transduced cells

Afamitresgene Autoleucel Group 3 + Expansion

Participants who received afamitresgene autoleucel 1.2-10x10\^9 transduced cells

Substudy: Low Dose Radiation (LDR) in Combination With Afamitresgene Autoleucel

Participants who received LDR in combination with lymphodepletion chemotherapy followed by the afamitresgene autoleucel infusion (1.2-10x10\^9 transduced cells).

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Afamitresgene Autoleucel, Group 13
Afamitresgene Autoleucel, Group 23
Afamitresgene Autoleucel Group 3 + Expansion32
Substudy: Low Dose Radiation (LDR) in Combination With Afamitresgene Autoleucel4

Reported measurements

Source class 1
Values in Weeks · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Afamitresgene Autoleucel, Group 119.8Not reported18.85720.714Not reported
Afamitresgene Autoleucel, Group 2NANot reportedNANAMedian overall survival was not reached in some arms at the time of data cutoff due to ongoing survival; therefore, median OS and associated confidence intervals are not reported for those arms.
Afamitresgene Autoleucel Group 3 + Expansion42.9Not reported25.429NAUpper confidence interval bounds were not estimable in some arms due to censoring
Substudy: Low Dose Radiation (LDR) in Combination With Afamitresgene AutoleucelNANot reported11.571NAMedian overall survival was not reached in some arms at the time of data cutoff due to ongoing survival; therefore, median OS and associated confidence intervals are not reported for those arms.
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        18.857
        upper Limit
        20.714
        value
        19.8
      2. comment
        Median overall survival was not reached in some arms at the time of data cutoff due to ongoing survival; therefore, median OS and associated confidence intervals are not reported for those arms.
        group Id
        OG001
        lower Limit
        NA
        upper Limit
        NA
        value
        NA
      3. comment
        Upper confidence interval bounds were not estimable in some arms due to censoring
        group Id
        OG002
        lower Limit
        25.429
        upper Limit
        NA
        value
        42.9
      4. comment
        Median overall survival was not reached in some arms at the time of data cutoff due to ongoing survival; therefore, median OS and associated confidence intervals are not reported for those arms.
        group Id
        OG003
        lower Limit
        11.571
        upper Limit
        NA
        value
        NA
denoms
  1. counts
    1. group Id
      OG000
      value
      3
    2. group Id
      OG001
      value
      3
    3. group Id
      OG002
      value
      32
    4. group Id
      OG003
      value
      4
    units
    Participants
description
OS was defined as the time from the date of afamitresgene autoleucel infusion to the date of death (due to any reason).
dispersion Type
95% Confidence Interval
groups
  1. description
    Participants who received afamitresgene autoleucel 0.1x10\^9 transduced cells
    id
    OG000
    title
    Afamitresgene Autoleucel, Group 1
  2. description
    Participants who received afamitresgene autoleucel 0.5-1.2x10\^9 transduced cells
    id
    OG001
    title
    Afamitresgene Autoleucel, Group 2
  3. description
    Participants who received afamitresgene autoleucel 1.2-10x10\^9 transduced cells
    id
    OG002
    title
    Afamitresgene Autoleucel Group 3 + Expansion
  4. description
    Participants who received LDR in combination with lymphodepletion chemotherapy followed by the afamitresgene autoleucel infusion (1.2-10x10\^9 transduced cells).
    id
    OG003
    title
    Substudy: Low Dose Radiation (LDR) in Combination With Afamitresgene Autoleucel
param Type
MEDIAN
reporting Status
POSTED
time Frame
From afamitresgene autoleucel infusion until death due to any reason or censored date From afamitresgene autoleucel infusion until death due to any reason or censored date
title
Overall Survival (OS)
type
SECONDARY
unit Of Measure
Weeks

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice